logo
logo

Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management

May 11, 2020•about 5 years ago

Amount Raised

$65 Million

Menlo Park

Description

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it has closed a $65 million convertible notes financing with a fund managed by Deerfield Management Company L.P. (“Deerfield”). The Company intends to use the proceeds from this financing for its commercial activities as well as general corporate purposes.

Company Information

Company

Intersect Ent

Location

Menlo Park, California, United States

About

Intersect ENT is a company transforming care for patients with ear, nose and throat conditions. The Company’s steroid-releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People